Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

During a subcutaneous injection, a short needle is used to inject a drug into the fatty tissue layer between the skin and the muscle, usually in specific areas of the thigh, arm, and abdomen.

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Despite flat overall Q2 2025 sales, Keytruda's continued strong performance in oncology supports long-term bullish prospects ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...

Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks in Goldman Sachs’ portfolio. On September 19, the company ...

One year into treatment with an every-6-month dose of the investigational drug lenacapavir (LEN, Gilead Sciences) in a dual-treatment combination, 88% of treatment-naive people living with HIV had ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...